A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536)
A Phase 1/2 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital ( Site 0140) — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Mayo Clinic Hospital ( Site 0140) — Scottsdale, Arizona
- UCLA Hematology & Oncology ( Site 0017) — Los Angeles, California
- Colorado Blood Cancer Institute ( Site 0225) — Denver, Colorado
- University of Michigan ( Site 0018) — Ann Arbor, Michigan
- Mayo Clinic - Rochester ( Site 0138) — Rochester, Minnesota
- Duke Cancer Center ( Site 0067) — Durham, North Carolina
- The Ohio State University Wexner Medical Center ( Site 0056) — Columbus, Ohio
- Tennessee Oncology, PLLC ( Site 0020) — Nashville, Tennessee
- UT Southwestern Medical Center ( Site 0116) — Dallas, Texas
- University of Utah, Huntsman Cancer Institute ( Site 0122) — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.